Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: An institutional tuberculosis outbreak

Clinical Infectious Diseases

Volumn 35, Issue 9, 2002, Pages 1106-1112

  Spradling, P ^a   Drociuk, D ^c   McLaughlin, S ^c   Lee, L M ^b   Peloquin, C A ^d   Gallicano, K ^e,f   Pozsik, C ^c   Onorato, I ^b   Castro, K G ^a   Ridzon, R ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c SOUTH CAROLINA DEPARTMENT OF HEALTH AND ENVIRONMENTAL CONTROL   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e Axelson Biopharma Research Inc   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMYCIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EPIDEMIC; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PRIORITY JOURNAL; PRISON; RASH; TUBERCULOSIS; UVEITIS; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE OUTBREAKS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; INSTITUTIONAL PRACTICE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PRISONERS; RIFABUTIN; TUBERCULOSIS;

EID: 0036827767     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/343047     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47:1-58.
2. Daley CL, Small PM, Schecter GF, et al. An outbr k of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231-5.
3. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
4. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-4.
5. Centers for Disease Control and Prevention. 1999 USPHS/DSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1999; 48(RR10):1-66.
6. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28:419-30.
7. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164:7-12.
8. Small PM, Fujiwara P. Management of tuberculosis in the United States. N Engl J Med 2001; 345:189-200.
9. Centers for Disease Control and Prevention. Notice to readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000; 49:185-9.
10. Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001; 70:149-58.
11. Narita M, Stambaugh J, Hollender E, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30:779-83.
12. Centers for Disease Control and Prevention. Drug-susceptible tuberculosis outbr k in a state correctional facility housing HIV-infected inmates: South Carolina, 1999-2000. MMWR Morb Mortal Wkly Rep 2000; 49:1041-4.
13. Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res 1991; 8:1437-40.
14. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997; 18:79-87.
15. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33:1237-41.
16. Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47: 983-1009.
17. Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: Relative bioavailability and food effect. Clin Pharmacol Ther 1992; 52: 335-41.
18. Dean AG, Dean JA, Coulombier D, et al. Epi Info, Version 6: A Word Processing, Database and Statistics Program for Epidemiology on Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention, 1994.
19. Graham NMH, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1 seropositive and seronegative intravenous drug users. JAMA 1992; 267:369-73.
20. Peloquin C. Serum concentration of the antimycobacterial drugs. Chest 1998; 113:1154-5.
21. Marzolini C, Chave J, Telenti A, Brenas-Chinchon L, Biollaz J. Impaired absorption of rifabutin by concomitant administration of didanosine. AIDS 2001; 15:2203-4.
22. Ungo J, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871-6.
23. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
24. Reindollar R. Hepatitis C and the correctional population. Am J Med 1999; 107:100S-3S.
25. Maher D, Chaulet P, Spinaci S, et al. Treatment of Tuberculosis: Guidelines for National Programmes. 2nd Ed. Geneva: World Health Organization, 1997.
26. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Lancet 1994; 344:1323-8.
27. Perriens J, Colebunders R, Karahunga C, et al. Increased mortality and tuberculosis treatment failure among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144:750-5.
28. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342:332-7.
29. Elliot A, Halwiindi B, Hayes R, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg 1995; 89:78-82.
30. Centers for Disease Control and Prevention. Notice to readers: acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214-5.